GleamWall
中文EN

NRIX Nurix Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1549595 · Fiscal year ends 11/30

Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY738.8%
TTM net income YoY220.5%
TTM EPS YoY181.8%
Revenue 3-yr CAGR117.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin41.3%
Net margin42.0%
FCF margin52.7%
EBITDA margin42.5%

Returns

ROE44.0%
ROA34.3%
ROIC (approx.)84.5%
Asset turnover0.82x

Leverage & solvency

Liabilities / assets19.0%
Debt / equity0.00x
Current ratio8.44x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-08-312026Q22026-05-312026Q12026-02-282025Q4*2025-11-302025Q32025-08-312025Q22025-05-312025Q12025-02-282024Q4*2024-11-30
Income statement
Revenue$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M
R&D expense$79.26M$87.65M$84.14M$83.02M$86.12M$78.10M$69.66M$67.22M
SG&A expense$34.35M$15.59M$14.61M$13.65M$13.16M$14.28M$11.65M$10.72M
Operating income$559.45M-$94.20M-$92.50M-$83.09M-$91.39M-$48.32M-$62.86M-$64.66M
Pretax income$563.41M-$89.81M—-$78.22M-$86.42M-$42.70M-$56.35M-$58.54M
Income tax$13.61M-$271,000$0$0$0$760,000$0$8,000
Net income$549.81M-$89.53M-$87.17M-$78.22M-$86.42M-$43.46M-$56.35M-$58.55M
EBITDA$561.59M-$91.95M-$90.30M-$80.97M-$89.36M-$46.08M-$60.51M-$62.11M
EPS (basic)4.93-0.81-0.79—-1.03-0.52-0.67—
EPS (diluted)4.73-0.81-0.79—-1.03-0.52-0.67—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)116.15M111.08M110.07M—84.16M83.88M83.56M—
Balance sheet
Cash & equivalents$720.24M$67.69M$71.19M$246.96M$78.44M$84.26M$75.92M$110.90M
Receivables$20.00M——$0—$19.00M—$0
Current assets$1.10B$456.48M$554.39M$606.82M$440.60M$515.33M$563.70M$619.39M
PP&E, net$19.41M$20.01M$21.70M$22.49M$20.50M$18.77M$18.45M$17.76M
Total assets$1.20B$535.54M$636.13M$688.13M$522.47M$591.55M$615.04M$669.34M
Current liabilities$130.74M$72.02M$92.20M$86.47M$82.35M$75.61M$89.99M$95.85M
Total liabilities$226.99M$132.91M$155.24M$149.39M$150.22M$143.95M$134.13M$142.35M
Shareholders' equity$968.31M$402.63M$480.89M$538.75M$372.25M$447.60M$480.92M$526.99M
Shares outstanding109.20M103.70M103.40M101.81M76.87M76.43M76.23M75.87M
Cash flow statement
Operating cash flow$615.63M-$96.57M-$71.91M-$67.83M-$57.38M-$63.16M-$61.09M-$48.75M
Capital expenditure$1.39M$1.94M$1.04M$5.13M$2.71M$2.67M$3.48M$2.10M
Free cash flow$614.24M-$98.51M-$72.96M-$72.96M-$60.10M-$65.84M-$64.57M-$50.86M
Investing cash flow$31.58M$93.00M-$123.83M$346,000$50.48M$71.50M$25.53M-$140.82M
Financing cash flow$5.16M$66,000$19.98M$236.01M$1.16M$6,000$1.47M$200.52M
Depreciation & amortization$2.14M$2.25M$2.20M$2.12M$2.03M$2.24M$2.35M$2.55M
Stock-based compensation$10.78M$11.39M$9.40M$9.09M$9.77M$10.38M$8.72M$8.51M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.